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ABSTRACT
Illicit drug use creates significant burden at societal, fam-
ily and personal levels. Every year substantial resources are
allocated for treatment and the consequences of illicit drug
use in Australia and around the world. Heroin is one of
the major forms of illicit drugs. Several independent heroin
treatment strategies or interventions exist and state-of-the-
art research demonstrates their efficacy and relative cost-
effectiveness. However, assessing total potential gains and
burden from providing all treatment interventions or varying
the mix of heroin treatments has never been attempted. This
paper proposed an individual-level simulation model (ISM)
which addresses net social benefit over a lifetime that can
accommodate the complexity of individuals going in and
out of multiple treatments and their corresponding costs and
benefits arising from different treatments during the life-course
of heroin users in the context of New South Wales (NSW)
Australia. This model is intended to serve as an effective
tool for economic evaluation and policy making in the illicit
drug area in Australia. The validity of the model has been
assessed by comparing short term outcomes or examining the
status of participants at a various points of time predicted
from the model with other data sets that were not used to
parameterise the model. Initial model results have been also
presented to highlight different types of scenario analysis that
can be conducted in future.
INTRODUCTION
This paper deals with the development of novel individual-
level simulation model (ISM) for health care decision making.
The model is developed for modelling range of treatments
available for illicit drug users. The model is simulated for long
term (generally lifetime of drug users) to evaluate treatment
services. Following paragraphs deal with the area of illicit drug
use. Governments, non-governmental organizations (NGOs)
and International Organizations worldwide invest hundreds of
billions of dollars in health care projects. Australia spends
around 10% of its GDP or AUD 100 billion per year in
recent years in health care WDI (2012). In the area of illicit
drug spending, Australian federal and state governments spend
about AUD 1.7 billion per annum in prevention, treatment,
harm reduction and law enforcement to combat illicit drugs.
There is an increasing pressure from both the government and
the public to know whether the current spending is optimal
or what needs to change to increase the benefits of spending.
This is particularly important for complicated policies where
there are many external costs and benefits, and as such; there
are diverse views about the value of the interventions.
Existing research demonstrates efficacy and relative cost-
effectiveness for individual heroin treatments, such as phar-
macotherapy maintenance. “Cost of illness” studies have es-
timated the total social burden related to all illicit drugs, and
have been important in communicating this burden. But these
studies do not provide evidence on the total potential gains
from all interventions. And neither of these approaches can be
used to value the net benefit, over the lifespan, of providing
a system of heroin treatment interventions. There is a press-
ing need to demonstrate whether the existing combinations
of heroin treatment interventions are a good investment for
government. The aim of this paper is to develop a modelling
approach which can assess the net social benefit of current
heroin treatment strategies, and compare different combina-
tions of treatment alternatives through modelled scenarios.
This will lead to better informed policy decisions about the
mix and type of treatments. The critical methodological issue
is the choice of modelling approach. The model needs to
capture recurring events over time as well as reflect alternative
trajectories for individuals who use heroin. The chosen model
is a micro-simulation model, also referred to as an ISM. It
depicts events and outcomes at the level of the individual. The
ISM enables ‘memory’ for each individual of such things as
the length of heroin use, past treatments and incarcerations.
This paper describes the rationale for an ISM and provides the
detailed methodology employed to develop the ISM of heroin
careers.
LITERATURE REVIEW
The decision problem of heroin use with recurring events
such as abstinence, crime, incarceration, and treatment over
time can be modelled using state transition models (STM).
STMs consist of set of mutually exclusive and collectively
exhaustive health states. Individuals can transition among
these health states based on prescribed transition probabilities.
Interactions between individuals are ignored in STMs. One of
the predominantly used STM in substance abuse literature is
cohort-based STM also know as Markov model (Schackman
et al. (2011)). Cohort-based STMs are relatively simpler to
develop when the number of health states is not large. These
models are restricted by the Markovian assumption, where
transition probabilities do not depend on individual history or
memory (i.e. past health states or state duration) Siebert et al.
(2012). In case of heroin use, it is recognised that individuals
history of incarceration, treatment, and length of time in
treatment has an effect on state transition of an individual
(Hser et al. (2004), Zhang et al. (2003)). Therefore, it is
necessary to include the information about individual history
while modelling heroin users based on STM. Cohort-based
model can handle memory by having additional health states to
include history, however, it often results in a very large model
which is difficult to handle. On the other hand, individual-
level simulation model (ISM) or individual-level STMs are
not restricted by the Markovian assumptions as they simulate
individuals history by using tracker variables. This greatly
reduces the number of health states required.
ISMs better represent heterogeneity among individuals in
complex modelling scenarios such as illicit drug use. ISMs
can model individual characteristics as continuous variables
whereby future decisions depend on current and past individual
history. In case of cohort-based STMs, individual characteris-
tics needs to be categorized to make separate health states
Siebert et al. (2012). The ISMs can easily handle individual
specific time steps as individuals in the model are simulated
one at a time.
MODEL OVERVIEW
The ISM model in this paper starts with the population
of individuals who have ever used heroin (previously and
currently) for the New South Wales (NSW) state of Australia.
These individuals are distributed in various health/treatment
states (eg, abstinence, irregular use, dependent use, various
treatment, prison and death states). Overall model working
is conceptually represented in Fig. 1. There are six model
components which are conceptually defined, namely, the initial
population, health states, state transitions, costs and outcomes
(these will be attached where relevant to being in a given state
i.e. treatment, prison, societal costs of crime), and net social
benefit.
The model starts with the initial population of current
heroin users and heroin abstainers. This population of indi-
viduals are transitioned from one health state to other us-
ing predefined (individual based) state transition probabilities.
After each state transition, outcomes such as heroin use,
crime committed; and resource implications are computed.
This process is repeated at each time step (where time step is
defined as the length of stay in each state, individually driven)
until the end of simulation time period is reached. Each year,
a sub-population of new drug initiators is added to the current
population to include new drug users, along with a mortality
rate which exists for the model). Finally, net social benefit
is computed based on the outcomes of the simulation model.
Following section provides more detail on each of the model
components.
Fig. 1. Model Overview
Initial Population
The initial population in the current model was estimated
based on the current NSW heroin using population. This
includes those currently abstinent, those in treatment subgroups
as well as those currently in heroin using subgroup. The
characteristics of the initial population that were selected
were age, gender, treatment history (number of episodes and
duration of treatment), HIV and Hepatitis-C status; which were
obtained from a number of data sources.
States
In the ISM, we have used three important locations (stages)
in the drug using individuals trajectory : i) in community, ii)
in prison, and iii) death.The first two stages are considered in
this study to model the cost, benefit and treatment variations
in drug using population. Exit from the model occurs if alive
at age 60, death from drug related or non-drug related causes.
Hence the total number of states is provided in Table I.
TABLE I. TOTAL NUMBER OF HEALTH STATES BASED ON HEROIN USE
AND STAGES
State Stage Description
Abstinence(S1) COMMUNITY not using
Irregular use(S2) COMMUNITY use irregularly




Residential rehab.(S5) COMMUNITY rehabilitation
Pharmacotherapy (S6) COMMUNITY provision of
safe opioid
Counselling Only(S7) COMMUNITY psychological
therapy
Prison No Treatment(S8) PRISON not in treatment
Treatment in Prison(S9) PRISON in treatment
Death or 60+ years old DEATH death from all
causes
Transition Time
In this model, an approach which provides heterogeneous
time to transition for each individual is used. We have used
length of stay (LOS) distributions for each individual. This is
due to the fact that previous research has shown that LOS is
highly predictive of subsequent drug use outcomes (Zhang et
al. (2003),Hser et al. (2004)).
The distributions of LOS of an episode is created and
assigned to each individual in the model. The LOS varies
depending on individual characteristics (such as previous treat-
ment episodes, age, gender, amount of drug use, state). The
LOS based on individual characteristics were used only where
sustained evidence exist (i.e. at least two empirical evidences
to confirm). See Table II for data sources. Two type of survey
dataset such as Alcohol and Other Drug Treatment Services
National Minimum Data Set (AODTS-NMDS) and Australian
Treatment Outcome Study (ATOS) have been used.
TABLE II. SUMMARY OF DATA SOURCES FOR LOS ESTIMATION
State LOS data sources
S1 ATOS Dataset;
Simpson and Marsh, 1986; Termorshuizen et al. (2005);
Hser et al. (2007); Shah et al. (2006);
Nosyk et al. (2013)
S2 ATOS Dataset; Gronbladh & Gunne (1989);
Coffin & Sullivan (2013)
S3 ATOS Dataset; Bell et al. (1997)
S4 ATOS Dataset; (AODTS-NMDS) Dataset
S5 ATOS Dataset; AODTS-NMDS Dataset
S6 ATOS; Burns et al. (2009)
S7 ATOS Dataset; AODTS-NMDS Dataset
S8, S9 average sentence for the crime type.
State Transitions
Once individuals in each state finish their assigned LOS
in a state, they transition to other state based on transition
probability functions. These functions are dependent upon
the individuals attributes. In the model, these probabilities
were estimated based on number of data sources. Australian
treatment and outcome study (ATOS) dataset, MIX dataset,
and relevant literature were used to estimate these probability
functions.
Costs and Outcomes
The individuals in the model transition from one state to
another and in this process costs and outcomes (also referred
to as rewards) are accrued. The resources were attached to
individual when they were in certain states and are referred
to as state awards. For example, while in S4 (withdrawal in
the community), the cost per day of withdrawal is attached;
similarly cost was attached to residential rehabilitation (by
days in RR); pharmacotherapy (by days in OTP); counselling
(by days); prison (days); treatment in prison (days in OTP).
Average unit costs by treatment type were applied.
The variation in resource use is driven by the length of time
in a state. There are resources attached to some transitions
(transition awards) i.e. transitioning into prison would incur
the costs of the police and court. Total costs include the
following components: (i) value of life-years (saved, or lost),
(ii) treatment costs; (iii) other health care utilisation (i.e.
treatment for specific diseases such as HIV, Hepatitis C), (iv)
crime and criminal justice system costs. Total benefits include:
earnings due to individuals returning to work after successful
treatments.
Net social benefit
Once the costs and benefits have been calculated, the
criterion for assessing the overall efficiency of an intervention
is the Net Social Benefit (NSB) Feldstein (1964). The main
costs and benefits will be calculated based on participants life
time trajectories, during which they may be employed, use
health care services, contract HIV or Hep C, commit crimes
and go to prison. The base model will characterize the status-
quo of behaviours of heroin users and calculate the base net
social cost-benefit of current heroin treatment arrangement in
NSW; different policy options can be explored to find the best
combination of treatments that gives the highest net social cost-
benefit.
DATA SOURCES FOR THE MODEL
Initial Population
The initial population for the model provides an estimate
for the number of individuals within each of the 9 states
in the model. States S10 was not included in the initial
population as this state relates to death. The figures for each
state were derived from various recent data sources discussed
in this section (where possible from years 2012-2013).The final
numbers have been rounded, to reflect the lack of precision in
the estimates (see Table III).













The proposed model simulated life trajectories of heroin
users in NSW based on the transition matrix, which lays out all
possible transitions from one state to the other state over partic-
ipants life time. The possible transitions are determined by the
availability of treatment modalities in NSW and characteristics
of heroin use such as initiation, developing to dependent use,
participating in treatment, abstinence, relapsing and so on. A
participant makes transition to one of mutually exclusive states
once he/she has completed a LOS for the episode. Multiple
datasets and published literature were used or combined to
estimate the parameters for transition functions.
Transitions from community states to community states:
ATOS was the primary dataset to estimate transition proba-
bility functions from community states to community states.
In addition, evidence from literature was used together with
ATOS estimates to determine the final transition probabilities.
Transitions from community states to prison states: Par-
ticipants in S1, S2, S3, S4, S5, S6 and S7 are allowed to
make transitions to prison states because of their previously
committed crimes. The primary data sources to estimate the
prison transition probabilities were the published results from
a study about engagement with criminal justice system among
opioid dependent people in NSW (Degenhardt et al. (2013)).
The alleged individuals (based on crime committed rates)
can be proved or pledged guilty. The weighted average prison
terms in the local and district courts by categories of offences
were used to assign length of stay to individuals who enter
prison (BOCSAR Court Data Report, 2012). All transition
probabilities of imprisonment from S1-S7 are dependent on
age, gender, and state history.
Transitions from prison states to community states: In-
dividuals can move to one of states in community on the
completion of their stay in prison.
Mortality
The model considered variety of mortality rates based on
the individual characteristics such as length of stay in the
current state and history of previous state. The data for these
mortality rates were derived from PHDAS, ATOS, and RCT
sample. The specific rates (crude mortality rates (CMR) per
1000 person years (PY)) used in the model are illustrated in
Table IV.
TABLE IV. MORTALITY RATES FOR EACH STATE
State: In State: From Time CMR (/1000PY)
S1 Any fixed 5.3 (5.0 to 5.6)
S2 Any fixed 5.3 (5.0 to 5.6)
S3 S1, S4, S5, S7 1st week 17.4 (11.7-25.0)
2nd week 20.1(13.8-28.4)
S8 1st 2 weeks 59.5(41.3-83.6)
out of prison
S2, S6, S10 Other time in S3 11.5(11.1-12.0)
S4 anywhere fixed 6.0(5.76.4)
S5 anywhere fixed 6.0(5.76.4)
S6 S3, S4, S5, S7, S8 1st week 39.5(31.9-48.8)
S10 1st week 10.9 (4.0-23.8)
S6 2nd week 17.0 (11.8-23.6)
S6 Other time in S6 5.6(5.2-5.9)
S7 S3,S4, S5, S6 fixed 6.0(5.7-6.4)
S8 anywhere fixed 2.7(2.0 - 3.7)
S9 anywhere fixed 0.7(0.3 to 1.2)
Estimating costs
Treatment costs: The primary source for resource use
information for treatment was extracted from individual care
plans developed for the National Drug and Alcohol-Clinical
Care and Prevention (DA-CCP). Care plans for opioid substi-
tution, withdrawal, residential rehabilitation, and counselling
for populations aged 18 to 64 were used. Information on
staff type and time, pharmaceuticals, diagnostics, overhead
and administrative allocations were obtained from respective
care packages for each treatment. Once identified, resources
were costed in 2012 AUD, sourced from NSW Wages and
Salaries, Medical Benefit Schedule, Pharmaceutical Benefits
Schedule (NSW Health 2015, PBS 2015, MBS (2015)). Costs
were estimated for an episode, and then a cost per day was
calculated for use in the model.
Criminal justice system costs: Unit costs were obtained
from multiple sources and were adjusted to 2012 AUD as
necessary. The average cost of a day in prison in NSW was
sourced from the Report on Government Services as was the
average cost per charge in the Magistrates Court (Productivity
Commission 2015). Social costs of crime were obtained from
an Australian report which included the intangible losses,
property losses, and medical costs by type of offence (Russell
et al. (2013)). The costs of policing were also estimated
(Byrnes et al 2012), with annual non-capital expenditure on
policing (Productivity Commission 2015).
Value of Statistical life year: According to Access Eco-
nomics (2008) the mean of value of a life from these 17
studies was $5.7 million (range $0.9 to $28.4 million 2006
AUD). After further analysis the recommendations from this
report suggest using $6.0 million 2006 AUD (range $3.7 to
$8.1 million). After adjusting to 2012 AUD with the CPI, the
value of a life was estimated to be $7.0 million (range$5.87
-$8. 34 million). This value was annuitized over 80 years with
a 3% discount rate. Then the total value over the remaining
expected lifespan was calculated.
Other health care utilization costs: Estimates of other
health care utilisation were estimated as daily costs. These
included utilisation of inpatient, emergency department, out-
patient services, general practitioners, specialists, and ambu-
lances by model state were obtained (NHC 2015, DoH 2014,
ASNSW 2015). These costs were then applied in the model
as relevant.
Benefits
Individuals who are in states S1, S2, S3, S6 and S7
can be employed. The probability of employment increased
if individuals maintained longer duration in abstinence and
pharmacotherapy treatment. It was assumed that the longer
duration of abstinence and in maintenance treatment increased
participants probability of employment. Probabilities of em-
ployment were derived from ATOS, MIX, and NSW Labour
Statistics 2012. If the participant is employed, the benefit was
calculated as equal to days of employment times earnings per
day; if the participant is unemployed, the benefit was equal
to zero. The mean weekly earnings by gender and age from
the Employee Earnings Statistics published by the Australian
Bureau of Statistics was used to calculate the total earnings in
a state.
HIV and Hep-C prevalence among heroin users
The Hep-C prevalence and incidence rates were estimated
from the literature (Shand et al. 2014) and the resulting
calculated indicated that there were 62,056 individuals that
were Hep-C infected. Then this number were split by applying
age and gender distribution. Further, different stages of Hep-
C infection was also considered. Another estimation indicated
that there will be 670 to 840 new cases of Hep-C each year.
It is estimated that there are between 12,500 and 15,000
cases of HIV in NSW (NSW HIV Strategy 2012-2015). The
number of cases attributable to IDU is approximately 2%; this
is based on data that the prevalence of HIV is 1-2% among
people attending NSPs (HIV Annual Surveillance Report,
2014). This equates to 300 existing cases of HIV in NSW
that are the result of drug use. Further, 458 new cases of HIV
in NSW in 2012, 18 of these cases were attributable to drug
use (16 male; 2 female).
MODEL VALIDATION AND RESULTS
The proposed simulation model was written in Java using
the Eclipse IDE. The computer program was written following
modular approach (object orient programming) for model
components. Several verification tests were defined for each
of the modules to verify the intermediate simulation outputs.
The logic for transition of individuals within the conceptual
model was matched with the output from the simulation model.
Additionally, we have randomly selected some individuals in
the simulation model and traced their behavior and matched
that against our conceptual model logic. We have verified in-
dividual transitions within the model. The transition summary
from the model was compared with the expected transition
summary which was derived after manually inputting the
values into the transition functions.
In terms of validation of the simulation model, we have
used face validation and cross-validation. In face validation,
we have conducted review meetings with the advisory group
consisting of experts from the illicit drug field. The individuals,
discrete health states, transition probabilities, costs, mortality,
infection rates, and other parameters were also developed in
conjunction with domain experts along with making simpli-
fying assumptions to create the conceptual model. We also
performed cross-validation by running the baseline simulation
model and comparing its output with the published literature.
Cross-validation to existing datasets and published lit-
erature: The datasets and published literature which were
not used for model building were used for cross validation
exercise. Data on the overall behavior of illicit drug users were
used for model validation. Following are some of the model
validation results:
1) We have compared the simulation results to expected
total number of individuals in S6. Estimates are
used from NOPSAD data for the OTP numbers in
treatment (on census day). According to this dataset,
there were 18,715 individuals in OST treatment in
NSW on the census day in 2012. It is expected that
this number will grow at about 3% overtime assuming
it will follow the previous trend. We compared this
number with the number of individuals in state S6 in
various simulated years. The rate of increase in the
heroin users in S6 (OST) from simulation model was
2.929% ( 1.03 - 3.69 at 95% CI).
2) Larney & Indig (2012) estimated that the proportion
of opioid-dependent prisoners receiving OST treat-
ment was 43%. Based on the model the percentage of
opioid-dependent prisoners receiving OST treatment
in prison was 41.07 (95% CI 40.48 – 41.65).
3) According to the published literature, 60% of commu-
nity participants are in some type of treatment. From
the simulation model, the proportion of dependent
users in some type of treatment was 48.71% (47.42-
55.89 at 95% CI).
4) Mortality rate for opiate related deaths in NSW,
according to Roxburgh and Burns (2012), was com-
pared with the rate of drug related deaths in the
proposed model. The drug related deaths in NSW
stated by Roxburgh and Burns (2012) for 15 - 54
years old population was 198 (at 95% CI 112 - 283)
from 1999–2008. This means that the drug related
mortality rate was 0.0029 (=283/97,592) - 0.00114
(=112/97,592) (at 95% CI). From the simulation
model, the rate of drug related deaths (for 18 to 54
years old) was 0.00308 (0.002730 - 0.003446 at 95%
CI), which is consistent with the rates reported by
Roxburgh and Burns (2012).
5) Abstinence rate for 11 year follow up for depen-
dent heroin users from ATOS study (Teesson et al.
presentation) was used for validation. It is stated
in the study that percentage of heroin dependent
population decreases from 97.6 % in baseline year
to 15.1 % in 11th year (85% decrease approx.).
Based on the simulation model, we observed 47%
decrease in heroin dependent population after 11
years. Similarly, percentage of dependent population
in current treatment has decreased by 74% (after 11
years of simulation) compared to 46% stated in the
Teesson et al. presentation.
6) Mortality rate for opiate related deaths in NSW,
according to Roxburgh and Burns (2012), was com-
pared with the rate of drug related deaths in the
proposed model. The drug related deaths in NSW
stated by Roxburgh and Burns (2012) for 15 - 54
years old population was 198 (at 95% CI 112–283)
from 1999-2008. This means that the drug related
mortality rate was 0.0029 (=283/97,592) - 0.00114
(=112/97,592) (at 95% CI). From the simulation
model, the rate of drug related deaths (for 18 to 54
years old) was 0.00308 (0.002730 - 0.003446 at 95%
CI), which is consistent with the rates reported by
Roxburgh and Burns (2012).
7) Abstinence rate for 11 year follow up for depen-
dent heroin users from ATOS study (Teesson et al.
presentation) was used for validation. It is stated
in the study that percentage of heroin dependent
population decreases from 97.6 % in baseline year
to 15.1 % in 11th year (85% decrease approx.).
Based on the simulation model, we observed 47%
decrease in heroin dependent population after 11
years. Similarly, percentage of dependent population
in current treatment has decreased by 74% (after 11
years of simulation) compared to 46% stated in the
Teesson et al. presentation.
Above-mentioned results indicate that the model results
are consistent with the published studies. After validation,
the results of the model which has been run for 25 years
is obtained. The initial population was evolved in time to
simulate population aging, individual transitions, HIV and
Hep-C infection, crime, employment, and mortality. The costs
and benefits was calculated based on individual life events. The
initial state summary obtained yearly for 25 years of simulation
model is illustrated in Fig. 2. The number of individuals who
are incarcerated every year (for 25 years of simulation) and the
type of crime is presented in Fig. 3. Costs such as state costs,
crime costs, value of life year costs, HIV & Hep-C treatment
costs, and family burden costs are presented in Fig. 4. The
mortality, HIV cases, and individuals with over 60 years of age
Fig. 2. State summary for 25 years of simulation
Fig. 3. Crime rates for 25 years of simulation
for 25 years of simulation is presented in Fig. 5. The current
Heroin using population and their HepC status is presented in
Fig. 6. The purpose of this paper was to showcase the model
workings, initial validation and results. These results of the
model can drive the discussion on government investments on
drug treatment policy and decision making. It can also be used
to simulate alternative policy scenarios, which is a topic of
future research.
DISCUSSION AND CONCLUSION
The ISM model developed in this paper has modelled range
of treatment services in community and prison stages, and used
variety of datasets from illicit drug user surveys and published
literature. Traditionally, variety of economic evaluations based
on simulation models in the field of illicit drug use had been
developed. Nevertheless, most of these existing models were
cohort-based models and lacks consideration for individual
histories and attributes. The major weakness of cohort-based
approach was that the future individual events did not depend
on prior events. Similar simplifications can lead to misleading
model based estimations. Individual sampling models based
on microsimulation are starting to be used in health-care
decision-making. These models have better ability to represent
heterogeneity that is required in complex modelling scenarios
Fig. 4. Projected costs for 25 years of simulation
Fig. 5. Mortality, HIV status, and individuals over 60 yrs of age
Fig. 6. Current Population of Heroin Users and their HepC status
such as illicit drug use. Individuals in these models can take
into account their histories to make decision on their next
transition without creating large number of health states. Var-
ious features of proposed model for heroin use were validated
against external datasets and published data in this field, which
were not used as an input for model parameterisation. The
model output seems coherent and does not significantly diverge
from external datasets.
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